Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 18/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30518407 | 1.00 | MAT2A (0.54) | MAT2ACYP11B1CYP11B2HTR2BHTR6 | |
| SCHEMBL24109624 | 0.87 | MAT2A (0.69) | MAT2A | |
| SCHEMBL24110094 | 0.84 | MAT2A (0.78) | MAT2A | |
| SCHEMBL24109554 | 0.77 | MAT2A (0.71) | MAT2A | |
| SCHEMBL29893575 | 0.77 | MAT2A (0.71) | MAT2A | |
| SCHEMBL30277843 | 0.76 | MAT2A (0.57) | MAT2A | |
| SCHEMBL24109555 | 0.76 | MAT2A (0.57) | MAT2A | |
| SCHEMBL24109556 | 0.75 | MAT2A (0.46) | MAT2A | |
| SCHEMBL24154771 | 0.73 | MAT2A (0.54) | MAT2A | |
| SCHEMBL30283089 | 0.73 | MAT2A (0.54) | MAT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4165040-B1 | 2-AMINOQUINAZOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES INC (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20230257377-A1 | 2-AMINOQUINAZOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230257377-A1 | 2-AMINOQUINAZOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230257377-A1 | 2-AMINOQUINAZOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2023-08-17 | — | — | US | disclosed |
| WO-2021252679-A1 | 2-AMINOQUINAZOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257377-A1 | 2-AMINOQUINAZOLINONE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | MAT2A, MAT2B, MAT1A | MAT2A 1/4885CYP11B1 2656/4885CYP11B2 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.